DeJohn Joseph A. 4
4 · ENDOLOGIX INC /DE/ · Filed Sep 11, 2012
Insider Transaction Report
Form 4
DeJohn Joseph A.
Vice President - Sales
Transactions
- Award
Common Stock
2012-09-09$12.62/sh+28,944$365,273→ 112,626 total
Footnotes (6)
- [F1]40% vesting to occur upon consecutive growth targets over several quarters.
- [F2]40% vesting to occur upon achievement of U.S. revenue target for a quarter.
- [F3]5% vesting to occur upon U.S.regulatory approval of a second-generation AFX device.
- [F4]5% vesting to occur upon the achievement of Nellix device revenue target for a month.
- [F5]5% vesting to occur upon U.S. regulatory approval of Ventana device.
- [F6]5% vesting to occur upon U.S. regulatory approval of Nellix device.